While HER2-targeted CAR-T cells are more advanced in clinical development, TCR-T cells have some superiorities, such as increased tumor penetration, that make them a potential alternative for patients in whom HER2-targeted therapies have failed due to dense or inaccessible tumor tissue, or when new antigen targets are needed to boost the immune response. Here, ERBB2 is linked to neoplasm.